0000000000754594

AUTHOR

D. Matamis

showing 3 related works from this author

Correction to: Potentially modifiable factors contributing to outcome from acute respiratory distress syndrome: the LUNG SAFE study (Intensive Care M…

2018

The members of the LUNG SAFE Investigators and the ESICM Trials Group were provided in such a way that they could not be indexed as collaborators on PubMed. The publisher apologizes for this error.

Critical Care and Intensive Care Medicine
researchProduct

Resolved versus confirmed ARDS after 24 h: insights from the LUNG SAFE study

2018

Purpose: To evaluate patients with resolved versus confirmed ARDS, identify subgroups with substantial mortality risk, and to determine the utility of day 2 ARDS reclassification. Methods: Our primary objective, in this secondary LUNG SAFE analysis, was to compare outcome in patients with resolved versus confirmed ARDS after 24 h. Secondary objectives included identifying factors associated with ARDS persistence and mortality, and the utility of day 2 ARDS reclassification. Results: Of 2377 patients fulfilling the ARDS definition on the first day of ARDS (day 1) and receiving invasive mechanical ventilation, 503 (24%) no longer fulfilled the ARDS definition the next day, 52% of whom initial…

MaleARDSmedicine.medical_treatmentlnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4]ARDS reassessment; ARDS Survival; Berlin criteria ARDS; Persisting ARDS;Critical Care and Intensive Care Medicineassisted ventilation0302 clinical medicineRisk Factors030212 general & internal medicinerisk factor AdultTidal volumecomparative studyeducation.field_of_studyRespiratory Distress SyndromeMortality rateRemission Inductiontidal volumeARDS reassessment; ARDS Survival; Berlin criteria ARDS; Persisting ARDS; Critical Care and Intensive Care MedicineARDS reassessmentartificial ventilationclinical trialimmunosuppressive treatmentadult respiratory distress syndromeMiddle AgedARDS SurvivalMonte Carlo methodmedicine.anatomical_structureclassificationpositive end expiratory pressureCardiologyDisease ProgressionSOFA scoredisease severityFemaleAdultmedicine.medical_specialtyPopulationdisease classificationArticleNO03 medical and health sciencesremissionlength of stayAnesthesiologyInternal medicinemedicinepneumoniaSequential Organ Failure Assessment ScoreHumanshumaneducationAgedMechanical ventilationhospital mortalityLungbusiness.industryRisk Factordisease associationRespiratory Distress Syndrome AdultPersisting ARDSmedicine.diseasemajor clinical studymortalityRespiration Artificialbreathing rate030228 respiratory systemdisease exacerbationBerlin criteria ARDSbusinessIntensive care medicine
researchProduct

Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: Lessons from the DAL…

2014

The aims of this study were to describe the variability in protein binding of teicoplanin in critically ill patients as well as the number of patients achieving therapeutic target concentrations. This report is part of the multinational pharmacokinetic DALI Study. Patients were sampled on a single day, with blood samples taken both at the midpoint and the end of the dosing interval. Total and unbound teicoplanin concentrations were assayed using validated chromatographic methods. The lower therapeutic range of teicoplanin was defined as total trough concentrations from 10 to 20 mg/L and the higher range as 10-30 mg/L. Thirteen critically ill patients were available for analysis. The followi…

Malevalidityvalidation proceInternational CooperationSettore MED/41 - Anestesiologiadrug protein bindingGastroenterologylaw.inventionPlasmaStaphylococcus infectionCritically ill patientsInterquartile rangelaw[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesAntibioticsantibiotic therapyPharmacology (medical)Pharmacology & PharmacyAntibiotics; Critically ill patients; Glycopeptides; Hypoalbuminaemia; ICU; Pharmacokinetics; Adult; Aged; Anti-Bacterial Agents; Chromatography; Critical Illness; Female; Humans; International Cooperation; Male; Middle Aged; Plasma; Protein Binding; Teicoplanin; Young Adult; Drug Monitoring; Microbiology (medical); Infectious Diseases; Pharmacology (medical)Antibiotics; Critically ill patients; Glycopeptides; Hypoalbuminaemia; ICU; Pharmacokinetics; Adult; Aged; Anti-Bacterial Agents; Chromatography; Critical Illness; Female; Humans; International Cooperation; Male; Middle Aged; Plasma; Protein Binding; Teicoplanin; Young Adult; Drug Monitoringclinical articleChromatographymedicine.diagnostic_testdrug dose regimencritical illneTeicoplaninHypoalbuminaemiaMedicine (all)articleGlycopeptidesclinical trialGeneral MedicineMiddle Agedtrough time concentrationdrug protein binding variabilityIntensive care unitGlycopeptides Antibiotics Critically ill patients Pharmacokinetics Hypoalbuminaemia ICU3. Good healthAnti-Bacterial Agentsantiinfective agentdrug distributionInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitologypriority journalmulticenter study (topic)Vancomycinblood samplingFemaleCritically ill patientDrug MonitoringHumanmedicine.drugProtein BindingMicrobiology (medical)Adultmedicine.medical_specialtyhigh performance liquid chromatographyarea under the curveCritical Illnessultraviolet spectroscopymid dose concentrationchemistryGlycopeptideMicrobiologyteicoplanin adultenterococcal infectionyoung adult Adultdrug clearanceYoung AdultTherapeutic indexPharmacokineticsInternal medicineAnti-Bacterial AgentmedicineHumanssteady statePharmacokineticsDosingAgedbusiness.industrydrug half lifeAntibioticrecommended drug doseAntibiotics; Critically ill patients; Glycopeptides; Hypoalbuminaemia; ICU; Pharmacokinetics; Adult; Aged; Anti-Bacterial Agents; Chromatography; Critical Illness; Female; Humans; International Cooperation; Male; Middle Aged; Plasma; Protein Binding; Teicoplanin; Young Adult; Drug Monitoring; Microbiology (medical); Infectious Diseases; Pharmacology (medical); Medicine (all)calibrationSurgerymulticenter studyTherapeutic drug monitoringdrug blood levelICU[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacologyfree plasma drug concentrationTeicoplaninbusinessmetabolism
researchProduct